G1 Therapeutics Inc. closed an underwritten public offering of 3,910,000 common shares at $29.50 apiece to raise proceeds of about $108.4 million.
The shares sold included 510,000 shares sold as part of the full exercise of the underwriters' option to buy additional shares.
J.P. Morgan Securities LLC and Cowen and Co. LLC served as joint book-running managers for the offering. Needham & Co. LLC and Wedbush Securities Inc. acted as lead managers, while BTIG LLC acted as co-manager for the offering.
Research Triangle Park, N.C.-based G1 Therapeutics is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of novel therapeutics to treat cancer.
